- Conditions
- Pouchitis, Pouches, Ileoanal, Pouch, Ileal
- Interventions
- Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pouchitis
- Interventions
- etrasimod, Placebo
- Drug
- Lead sponsor
- Maia Kayal
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pouchitis
- Interventions
- Short-Chain Fructooligosaccharide, Maltodextrin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ulcerative Colitis, Pouchitis
- Interventions
- Intestinal Ultrasound
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pouchitis
- Interventions
- Biologically active human fecal material, OpenBiome
- Drug
- Lead sponsor
- Najwa Elnachef
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pouchitis
- Interventions
- Active FMT, then open label FMT, Placebo FMT, then open label FMT
- Biological
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Pouchitis, Ulcerative Colitis
- Interventions
- Observational, No intervention
- Other
- Lead sponsor
- Alimentiv Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York • Cleveland, Ohio
- Conditions
- Ulcerative Colitis, Pouchitis
- Interventions
- ursodiol (ursodeoxycholic acid, UDCA)
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pouchitis
- Interventions
- Electronic Barostat
- Procedure
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pouchitis
- Interventions
- Vedolizumab Placebo, Ciprofloxacin, Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more
- Conditions
- Pouchitis, Irritable Pouch Syndrome
- Interventions
- Liraglutide Pen Injector, Placebo Pen Injector
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Ulcerative Colitis, Pouchitis, Ileitis, Inflammatory Bowel Disease
- Interventions
- Clotrimazole
- Drug
- Lead sponsor
- Web
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pouchitis
- Interventions
- AST-120
- Drug
- Lead sponsor
- Ocera Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pouchitis
- Interventions
- CLF065, Placebo
- Drug
- Lead sponsor
- Calibr, a division of Scripps Research
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- La Jolla, California • Los Angeles, California • New York, New York
- Conditions
- Pouchitis
- Interventions
- Low FODMAP Diet, Regular Diet
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pouchitis
- Interventions
- AMT-101 (oral)-Dose A, AMT-101 (oral)-Dose B
- Drug
- Lead sponsor
- Applied Molecular Transport
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 12
- States / cities
- Bristol, Connecticut • Chicago, Illinois • Chevy Chase, Maryland + 9 more
- Conditions
- Pouchitis, Crohn's Disease, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Pouch, Ileal
- Interventions
- Mesenchymal Stem Cells (MSCs)
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Ileal Pouch
- Interventions
- EXE-346, Placebo
- Biological · Other
- Lead sponsor
- Exegi Pharma, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 5 more
- Conditions
- Pouchitis
- Interventions
- Alicaforsen, Placebo
- Drug
- Lead sponsor
- Atlantic Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 8 more
- Conditions
- Pouchitis
- Interventions
- Rifaximin 550 MG Oral Tablet [XIFAXAN]
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Chapel Hill, North Carolina
- Conditions
- Pouchitis, Ileal Pouchitis, Ileal Pouch
- Interventions
- Tofacitinib 10 mg
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Chronic Pouchitis, Pouchitis
- Interventions
- Fecal Microbiota Transplant (FMT)
- Drug
- Lead sponsor
- Maia Kayal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn Ileitis, Crohn Disease of Ileum, Crohn's Disease Relapse, Crohn's Gastritis, Crohns Disease Aggravated, Crohn Disease in Remission, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Disease of Pylorus, Crohn's Esophagitis, Crohn's
- Interventions
- No intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Pouchitis
- Interventions
- AST-120
- Drug
- Lead sponsor
- Ocera Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota